NovaBridge Biosciences (NBP) Total Current Liabilities (2018 - 2025)

NovaBridge Biosciences (NBP) has reported Total Current Liabilities for 8 consecutive years, with $26.9 million the latest figure, recorded in Q4 2025.

• Quarterly Total Current Liabilities rose 218.12% year-over-year to $26.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $26.9 million (up 218.12% YoY) and the FY2025 annual result came in at $26.9 million, up 218.12% from the prior year.
• Total Current Liabilities grew to $26.9 million in Q4 2025 per NBP's latest filing, from $16.1 million in the prior quarter.
• Over the last five years, Total Current Liabilities for NBP reached as high as $97.6 billion in Q4 2021 and fell as low as $2.0 million in Q2 2024.
• A 5-year average of $7.5 billion and a median of $26.9 million in 2025 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2021 — Total Current Liabilities surged 112170.09% — and 2022, when it plunged 99.89%.
• Year by year, Total Current Liabilities stood at $97.6 billion in 2021, then tumbled by 99.89% to $106.6 million in 2022, then sank by 46.35% to $57.2 million in 2023, then plunged by 85.22% to $8.5 million in 2024, then jumped by 218.12% to $26.9 million in 2025.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $26.9 million, $16.1 million, and $7.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.